drugset / Trial / NCT01979510
Safety and Efficacy Study of an Etoricoxib and Tizanidine Fixed Dose Combination in Participants With Moderate to Severe Acute Low Back Pain (MK-0663B-164)
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of this study is to evaluate the safety and tolerability of MK-0663B (etoricoxib/tizanidine) among participants with moderate-to-severe acute low back pain.
Timeline
- Start
- 2013-11
- Primary completion
- 2014-05
- Completion
- 2014-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etoricoxib | Small molecule | 90 mg | — |
| Subject | Meloxicam | Small molecule | 7.5 mg | — |
| Subject | Methocarbamol | Small molecule | 215 mg | — |
| Subject | Tizanidine | Small molecule | 6 mg | — |
| Background | Acetaminophen | Small molecule | 500 mg | — |
Indications
No indication recorded.